1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Gastro-esophageal Adenocarcinoma - Epidemiology Forecast-2030

Gastro-esophageal Adenocarcinoma - Epidemiology Forecast-2030

  • February 2021
  • 100 pages
  • ID: 6028053
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Gastro-esophageal Adenocarcinoma-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Gastro-esophageal Adenocarcinoma, historical and forecasted epidemiology as well as the Gastro-esophageal Adenocarcinoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Gastro-esophageal Adenocarcinoma Understanding
Gastroesophageal adenocarcinoma includes esophageal adenocarcinoma, gastroesophageal junctional adenocarcinoma, and gastric adenocarcinoma. There is an increasing trend in the incidence of these cancers in the 7MM.
Gastroesophageal cancer (GEC), comprising proximal esophagogastric junction (EGJ) and distal gastric cancer (GC), is a significant public health concern. The epidemiology of these tumors has significantly changed over the past several decades especially in developed countries. There is a recognized decrease in incidence and mortality of distal GC and an increase in incidence and mortality of proximal EGJ cancer.
Anatomically, gastroesophageal cancer (GEC) is comprised of two recognized tumor types, according to the 2010 American Joint Committee on Cancer (AJCC) TNM staging system. The first is esophageal/esophagogastric adenocarcinoma, herein referred to as EGJ cancers, entailing tumors arising between 5 cm proximal to the z-line (the endoscopic landmark demarcating the esophagus/stomach boundary) and 5 cm distal to the z-line into the stomach (gastric cardia). The EGJ encompasses the traditional Siewert EGJ classifications I, II, and III. Type I Siewert EGJ is considered esophageal adenocarcinoma. The second recognized tumor type is gastric adenocarcinoma (GC), also termed ‘non-cardia’ GC, referring to tumors arising anywhere 5 cm distal from the z-line to the pylorus.
Gastro-esophageal Adenocarcinoma Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Gastro-esophageal Adenocarcinoma, Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma, and HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Gastro-esophageal Adenocarcinoma Detailed Epidemiology Segmentation
• As per the analysis, there was a total of 211,383 Gastro-esophageal Adenocarcinoma incident cases in 2020, increasing at a CAGR of 1.54% for the study period 2018–2030.
• Japan showed the highest incident population of Gastro-esophageal Adenocarcinomas, as compared to other 7MM countries in 2020 which was 115,627.
• Among the European 5 countries, Germany had the highest incident population of Gastro-esophageal Adenocarcinoma with 13,881 cases, followed by the United Kingdom with 13,366 cases, in 2020.
• Epidemiology model for Gastro-esophageal Adenocarcinoma estimates that out of the total incident population of 40,423 cases in the US, in 2020, 29,480 and 10,943 cases were contributed by males and females, respectively.
• In 2020, the incident cases of Gastro-esophageal Adenocarcinoma in Stage IV were 18,318. Remaining Stage I, Stage II, and Stage III contributed to 6,872, 5,838, and 7,793 cases from the total incident cases.
• In 2020, the grade-specific incident cases for Grade I, Grade II, Grade III, and Grade IV were 1,617, 10,237, 25,284, and 808, in the US.
• HER2 positive Gastro-esophageal Adenocarcinomas was found in 7,648 incident cases in the United States, in 2020.

Scope of the Report
• The report covers the descriptive overview of Gastro-esophageal Adenocarcinoma, explaining its causes, genomics, staging, and other parameters.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Gastro-esophageal Adenocarcinoma.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Gastro-esophageal Adenocarcinoma, Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma, and HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma.

Report Highlights
• 10-Year Forecast of Gastro-esophageal Adenocarcinoma
• 7MM Coverage
• Total Incident Cases of Gastro-esophageal Adenocarcinoma
• Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma
• Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma
• Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma
• HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma

Key Questions Answered
• What are the disease risk, burdens, and unmet needs of Gastro-esophageal Adenocarcinoma?
• What is the historical Gastro-esophageal Adenocarcinoma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Gastro-esophageal Adenocarcinoma at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Gastro-esophageal Adenocarcinoma?
• Out of the above-mentioned countries, which country would have the highest incident population of Gastro-esophageal Adenocarcinoma during the forecast period (2021–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy
The Gastro-esophageal Adenocarcinoma report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Gastro-esophageal Adenocarcinoma epidemiology forecast.
• The Gastro-esophageal Adenocarcinoma epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Gastro-esophageal Adenocarcinoma epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2018–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on